NO20076475L - Enkeltdomene VHH antilegemer mot Van Willebrand faktor - Google Patents

Enkeltdomene VHH antilegemer mot Van Willebrand faktor

Info

Publication number
NO20076475L
NO20076475L NO20076475A NO20076475A NO20076475L NO 20076475 L NO20076475 L NO 20076475L NO 20076475 A NO20076475 A NO 20076475A NO 20076475 A NO20076475 A NO 20076475A NO 20076475 L NO20076475 L NO 20076475L
Authority
NO
Norway
Prior art keywords
nanobodies
polypeptides
willebrand factor
antibodies against
single domain
Prior art date
Application number
NO20076475A
Other languages
English (en)
Norwegian (no)
Inventor
Karen Silence
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx Nv filed Critical Ablynx Nv
Publication of NO20076475L publication Critical patent/NO20076475L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20076475A 2005-05-20 2007-12-17 Enkeltdomene VHH antilegemer mot Van Willebrand faktor NO20076475L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68347405P 2005-05-20 2005-05-20
PCT/EP2006/004773 WO2006122825A2 (en) 2005-05-20 2006-05-19 Single domain vhh antibodies against von willebrand factor

Publications (1)

Publication Number Publication Date
NO20076475L true NO20076475L (no) 2008-02-18

Family

ID=37431613

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20076475A NO20076475L (no) 2005-05-20 2007-12-17 Enkeltdomene VHH antilegemer mot Van Willebrand faktor
NO20190279A NO345342B1 (no) 2005-05-20 2019-02-27 Enkeltdomene VHH antistoffer mot Van Willebrand faktor
NO2021020C NO2021020I1 (no) 2005-05-20 2021-05-20 kaplasizumab

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20190279A NO345342B1 (no) 2005-05-20 2019-02-27 Enkeltdomene VHH antistoffer mot Van Willebrand faktor
NO2021020C NO2021020I1 (no) 2005-05-20 2021-05-20 kaplasizumab

Country Status (28)

Country Link
US (3) US7807162B2 (member.php)
EP (4) EP2444424B1 (member.php)
JP (1) JP4986997B2 (member.php)
KR (1) KR101414438B1 (member.php)
CN (1) CN101213214B (member.php)
AU (1) AU2006249090B2 (member.php)
BE (1) BE2019C503I2 (member.php)
BR (1) BRPI0609797B8 (member.php)
CA (2) CA2608873C (member.php)
CY (2) CY1122579T1 (member.php)
DK (1) DK2444424T3 (member.php)
ES (2) ES2694247T3 (member.php)
FR (1) FR19C1005I2 (member.php)
HU (2) HUE039846T2 (member.php)
IL (2) IL187168A (member.php)
LT (2) LT2444424T (member.php)
LU (1) LUC00099I2 (member.php)
MX (1) MX2007014564A (member.php)
NL (1) NL300966I2 (member.php)
NO (3) NO20076475L (member.php)
NZ (1) NZ563392A (member.php)
PL (2) PL2444424T3 (member.php)
PT (2) PT2444424T (member.php)
RU (1) RU2433139C2 (member.php)
SI (1) SI2444424T1 (member.php)
TR (1) TR201815552T4 (member.php)
WO (1) WO2006122825A2 (member.php)
ZA (1) ZA200709570B (member.php)

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE512364T1 (de) 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
ES2440990T5 (es) 2004-07-22 2022-10-25 Univ Erasmus Med Ct Rotterdam Moléculas de unión
AU2006205900B8 (en) * 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
WO2008049881A2 (en) * 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
AU2007336243B2 (en) 2006-12-19 2012-07-26 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
AU2007336242B2 (en) 2006-12-19 2012-08-30 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2121757A2 (en) * 2007-02-21 2009-11-25 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
KR101264473B1 (ko) * 2007-05-24 2013-05-29 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
AU2008270274B2 (en) 2007-07-03 2012-06-28 Ablynx N.V. Providing improved immunoglobulin sequences by mutating CDR and/or FR positions
US8975382B2 (en) 2007-11-27 2015-03-10 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
AU2009210275C1 (en) * 2008-01-29 2013-08-29 Ablynx N.V. Methods to stabilize proteins and polypeptides
JP2011525476A (ja) * 2008-03-05 2011-09-22 アブリンクス エン．ヴェー． 新規の抗原結合二量体複合体、その製造方法及び使用
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン．ヴェー． Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
US9034325B2 (en) 2008-07-22 2015-05-19 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
DK2387583T3 (en) * 2009-01-14 2019-01-14 Ablynx Nv PULMONAL ADMINISTRATION OF VARIABLE IMMUNGLOBULIN SINGLE DOMAINS AND CONSTRUCTIONS THEREOF.
US10005830B2 (en) * 2009-03-05 2018-06-26 Ablynx N.V. Antigen binding dimer-complexes, methods of making/avoiding and uses thereof
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
GB0905023D0 (en) * 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
PL2424889T3 (pl) 2009-04-30 2016-01-29 Ablynx Nv Sposób wytwarzania przeciwciał domenowych
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
FI3725330T3 (fi) 2009-09-03 2025-11-14 Ablynx Nv Polypeptidien stabiilit valmisteet ja niiden käyttötarkoitukset
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
WO2011067160A1 (en) 2009-12-01 2011-06-09 Ablynx Nv Von willebrand factor specific binding agents and uses thereof
LT3309176T (lt) 2009-12-14 2026-01-26 Ablynx N.V. Imunoglobulino vieno kintamojo domeno antikūnai nuo ox40l, konstruktai ir jų terapinis naudojimas
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
JP2013518853A (ja) 2010-02-05 2013-05-23 アブリンクス エン．ヴェー． 血清アルブミンと結合することが可能なペプチド並びにこれを含む化合物、構築物及びポリペプチド
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098518A2 (en) 2010-02-11 2011-08-18 Ablynx Nv Delivery of immunoglobulin variable domains and constructs thereof
AU2011214299B2 (en) 2010-02-11 2014-07-31 Ablynx Nv Methods and compositions for the preparation of aerosols
CN102781962B (zh) 2010-03-03 2014-12-10 阿布林克斯公司 双互补位A-β结合多肽
EP2552962B1 (en) 2010-03-26 2016-03-23 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2013174537A1 (en) 2012-05-24 2013-11-28 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
PH12012502272A1 (en) 2010-05-20 2017-07-26 Ablynx Nv Biological materials related to her3
WO2011161263A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Pharmaceutical compositions for cutaneous administration
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
ES2660895T3 (es) 2010-10-29 2018-03-26 Ablynx N.V. Método para la producción de dominios variables individuales de inmunoglobulina
CU24111B1 (es) 2010-11-08 2015-08-27 Novartis Ag Polipéptidos que se enlazan a cxcr2
AU2012234284B2 (en) * 2011-03-28 2015-10-08 Ablynx Nv Bispecific anti-CXCR7 immunoglobulin single variable domains
ES2688591T3 (es) 2011-03-28 2018-11-05 Ablynx N.V. Método para producir formulaciones sólidas que comprenden dominios variables individuales de inmunoglobulina
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP3590950A1 (en) 2011-05-09 2020-01-08 Ablynx NV Method for the production of immunoglobulin single varible domains
WO2012163887A1 (en) 2011-05-27 2012-12-06 Ablynx Nv Inhibition of bone resorption with rankl binding peptides
EP4350345A3 (en) 2011-06-23 2024-07-24 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
JP2014525736A (ja) 2011-06-23 2014-10-02 アブリンクス エン．ヴェー． ＩｇＥに対する免疫グロブリン単一可変ドメイン
EP3020728A1 (en) 2011-06-23 2016-05-18 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
PH12022550310A1 (en) * 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
TW201321405A (zh) * 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
US20150158934A1 (en) 2011-09-09 2015-06-11 Ucl Business Plc Broadly neutralizing vhh against hiv-1
WO2013041722A1 (en) 2011-09-23 2013-03-28 Ablynx Nv Prolonged inhibition of interleukin-6 mediated signaling
DE102011121238A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
DE102011121237A1 (de) 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
SG11201408037SA (en) * 2012-06-08 2015-01-29 Glenmark Pharmaceuticals Sa Humanized anti-trka antibodies with amino acid substitutions
WO2014087010A1 (en) 2012-12-07 2014-06-12 Ablynx N.V. IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
CN105102478A (zh) 2013-01-30 2015-11-25 弗拉芒区生物技术研究所 用于筛选和药物发现目的的新型嵌合多肽
AU2014214054B2 (en) 2013-02-05 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Muscarinic acetylcholine receptor binding agents and uses thereof
WO2014141192A1 (en) 2013-03-15 2014-09-18 Erasmus University Medical Center Generation of heavy chain-only antibodies
WO2014140376A1 (en) 2013-03-15 2014-09-18 Vib Vzw Anti-macrophage mannose receptor single variable domains for use in cardiovascular diseases
NL1040254C2 (en) 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
HK1223374A1 (zh) * 2013-06-13 2017-07-28 Bioverativ Therapeutics Inc. 抗fviii抗体或其用途
EP3099707B1 (en) 2014-01-30 2021-12-29 Vib Vzw Opioid receptor binding agents and uses thereof
WO2015158851A1 (en) * 2014-04-16 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
WO2015173325A2 (en) 2014-05-16 2015-11-19 Ablynx Nv Improved immunoglobulin variable domains
US11009511B2 (en) 2014-05-16 2021-05-18 Ablynx N.V. Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies
NL2013007B1 (en) * 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
PT3194976T (pt) 2014-07-22 2020-07-03 Univ Brussel Vrije Métodos para selecionar agentes que estabilizam complexos proteicos
PL3204018T3 (pl) 2014-10-07 2022-01-03 Immunomedics, Inc. Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
PL3233910T3 (pl) 2014-12-19 2020-06-01 Ablynx N.V. Dimery nanociał połączone cysteiną
EP3277316B1 (en) 2015-04-02 2025-03-05 Ablynx N.V. Bispecific cxcr4-cd-4 polypeptides with potent anti-hiv activity
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
AU2016260909B2 (en) 2015-05-13 2019-08-22 Ablynx N.V. T cell recruiting polypeptides based on CD3 reactivity
PT3611192T (pt) 2015-05-13 2025-06-12 Ablynx Nv Polipéptidos de recrutamento de células t com base na reatividade do tcr alfa/beta
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
US9708412B2 (en) 2015-05-21 2017-07-18 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
EP3316885B1 (en) 2015-07-01 2021-06-23 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CA2991637C (en) 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
NO2768984T3 (member.php) 2015-11-12 2018-06-09
CN115925919A (zh) 2015-11-13 2023-04-07 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白可变结构域
KR102095140B1 (ko) 2015-11-18 2020-03-31 머크 샤프 앤드 돔 코포레이션 Ctla4 결합제
MA43258A (fr) * 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1/ctla4
AU2016357460B2 (en) 2015-11-18 2023-07-27 Ablynx Nv Improved serum albumin binders
CN108473561B (zh) 2015-11-27 2022-12-16 埃博灵克斯股份有限公司 抑制cd40l的多肽
JP7096458B2 (ja) * 2016-01-26 2022-07-06 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 抗ｖｗｆ ｄ’ｄ３単一ドメイン抗体及びそれを含むポリペプチド
US20190127447A1 (en) 2016-05-02 2019-05-02 Ablynx N.V. Treatment of rsv infection
BR112018072953A2 (pt) * 2016-05-13 2019-02-19 Medimmune, Llc polipeptídeos de fusão de cd40l-fc e métodos de uso dos mesmos
ES3036522T3 (en) 2016-05-20 2025-09-19 Harpoon Therapeutics Inc Single chain variable fragment cd3 binding proteins
WO2017201488A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
PL3475699T3 (pl) 2016-06-23 2022-09-26 Ablynx N.V. Ulepszone oznaczenia farmakokinetyczne dla pojedynczych domen zmiennych immunoglobuliny
WO2018007442A1 (en) 2016-07-06 2018-01-11 Ablynx N.V. Treatment of il-6r related diseases
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
US11098113B2 (en) 2016-09-15 2021-08-24 Vib Vzw Immunoglobulin single variable domains directed against macrophage migration inhibitory factor
IL266506B2 (en) 2016-11-16 2025-05-01 Ablynx Nv T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta
WO2018098356A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
EP3544997A4 (en) 2016-11-23 2020-07-01 Harpoon Therapeutics, Inc. PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
US11414480B2 (en) 2016-12-07 2022-08-16 Ablynx N.V. Serum albumin binding immunoglobulin single variable domains
JP7300385B2 (ja) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
AU2018209151B2 (en) 2017-01-17 2025-02-27 Ablynx Nv Improved serum albumin binders
TW202444416A (zh) 2017-02-01 2024-11-16 耶魯大學 心臟衰竭及心腎症候群之精準治療
US11964002B2 (en) 2017-02-28 2024-04-23 Vib Vzw Means and methods for oral protein delivery
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
AU2018241286B2 (en) 2017-03-31 2025-03-13 Ablynx N.V. Improved immunogenicity assays
US10865238B1 (en) * 2017-05-05 2020-12-15 Duke University Complement factor H antibodies
EP3621990A1 (en) 2017-05-11 2020-03-18 VIB vzw Glycosylation of variable immunoglobulin domains
CN113896792B (zh) 2017-05-12 2025-08-22 哈普恩治疗公司 间皮素结合蛋白质
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
LT3630847T (lt) 2017-06-02 2024-12-10 Merck Patent Gmbh Adamts surišantys imunoglobulinai
TW202428621A (zh) 2017-06-02 2024-07-16 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
KR102778120B1 (ko) 2017-06-02 2025-03-06 메르크 파텐트 게엠베하 Mmp13 결합성 면역글로불린
KR102800125B1 (ko) * 2017-06-02 2025-04-24 아블린쓰 아그레칸 결합 면역글로불린
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
BR112020007196A2 (pt) 2017-10-13 2020-12-01 Harpoon Therapeutics, Inc. proteínas triespecíficas e métodos de uso
JP7760115B2 (ja) 2017-10-31 2025-10-27 フエー・イー・ベー・フエー・ゼツト・ウエー 新規抗原結合性キメラタンパク質とその方法及び使用
US20200199206A1 (en) * 2017-12-08 2020-06-25 AC Thera, LLC Bacterial toxin-neutralizing nanobodies and methods of making and using the same
MY201934A (en) 2018-01-05 2024-03-25 Novo Nordisk As Methods for treating il-6 mediated inflammation without immunosuppression
WO2019151865A1 (en) 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
AU2019217584B2 (en) 2018-02-06 2025-08-14 Ablynx Nv Methods of treating initial episode of TTP with immunoglobulin single variable domains
WO2019156566A1 (en) 2018-02-12 2019-08-15 Umc Utrecht Holding B.V. Bispecific molecules comprising gamma-delta tcr and t-cell or nk cell binding domain
WO2019155041A1 (en) 2018-02-12 2019-08-15 Vib Vzw Gβγ COMPLEX ANTIBODIES AND USES THEREOF
WO2019162521A1 (en) 2018-02-26 2019-08-29 Ablynx Nv Improved nucleotide sequences encoding peptide linkers
US11858960B2 (en) 2018-03-01 2024-01-02 Vrije Universiteit Brussel Human PD-L1-binding immunoglobulins
JP2021519093A (ja) 2018-03-27 2021-08-10 ユーエムシー ユトレヒト ホールディング ビー．ブイ． 微小血管血栓症の処置のための標的化血栓溶解
BR112020023330A2 (pt) 2018-05-14 2021-04-20 Harpoon Therapeutics, Inc. porção de ligação para ativação condicional de moléculas de imunoglobulina
WO2019226050A2 (en) 2018-05-24 2019-11-28 Wageningen Universiteit Novel viral anti-infective reagents
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
EP3636657A1 (en) 2018-10-08 2020-04-15 Ablynx N.V. Chromatography-free antibody purification method
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2020130838A2 (en) 2018-12-21 2020-06-25 Qvq Holding B.V. Antibodies for preventing or treating candidiasis
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
CA3135700A1 (en) 2019-04-02 2020-10-08 Immunetune B.V. Immune-stimulatory compositions and use thereof
KR20240160655A (ko) 2019-04-29 2024-11-11 콘포 테라퓨틱스 엔.브이. 트랜스맴브레인 단백질, 특히 gpcr과 함께 사용하기 위한 스크리닝 방법 및 검정
WO2020221888A1 (en) 2019-04-30 2020-11-05 Vib Vzw Cystic fibrosis transmembrane conductance regulator stabilizing agents
JP7701273B2 (ja) 2019-05-01 2025-07-01 ノヴォ ノルディスク アー／エス 抗ｉｌ－６抗体製剤
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
US20220220197A1 (en) 2019-05-28 2022-07-14 Vib Vzw Cancer Treatment by Targeting Plexins in the Immune Compartment
US12472254B2 (en) 2019-05-28 2025-11-18 Vib Vzw CD8+ T-cells lacking plexins and their application in cancer treatment
WO2021025556A1 (en) 2019-08-05 2021-02-11 Stichting Vu Identification and elimination of hcmv-infected cells
WO2021039574A1 (ja) * 2019-08-23 2021-03-04 株式会社カネカ Ｏ結合型糖鎖修飾が抑制された重鎖抗体
EP3799881A1 (en) 2019-10-04 2021-04-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Single domain antibodies specifically binding globo - series glycans
US20220380456A1 (en) 2019-10-21 2022-12-01 Vib Vzw Nanodisc-specific antigen-binding chimeric proteins
IL292879B2 (en) 2019-11-11 2025-08-01 Ibi Ag Innovative Bio Insecticides Ltd Nanoantibodies for insect control and their uses
WO2021105438A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
GB201918279D0 (en) 2019-12-12 2020-01-29 Vib Vzw Glycosylated single chain immunoglobulin domains
US20240027467A1 (en) 2019-12-20 2024-01-25 Vib Vzw Nanobody Exchange Chromatography
WO2021140205A1 (en) 2020-01-10 2021-07-15 Confo Therapeutics N.V. Methods for generating antibodies and antibody fragments and libraries comprising same
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
AU2021224851A1 (en) 2020-02-21 2022-09-15 Harpoon Therapeutics, Inc. FLT3 binding proteins and methods of use
WO2021170540A1 (en) 2020-02-25 2021-09-02 Vib Vzw Leucine-rich repeat kinase 2 allosteric modulators
JP2023523600A (ja) 2020-04-22 2023-06-06 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体
WO2021229104A1 (en) 2020-05-15 2021-11-18 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
CA3182883A1 (en) * 2020-06-26 2021-12-30 Christoph Hagemeyer Anti-vwf antibodies and uses thereof
JP2023532726A (ja) * 2020-06-29 2023-07-31 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗プロテインｓシングルドメイン抗体及びそれを含むポリペプチド
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
AR122933A1 (es) 2020-07-10 2022-10-19 Novo Nordisk As Métodos para tratar la enfermedad cardiovascular
WO2022063957A1 (en) 2020-09-24 2022-03-31 Vib Vzw Biomarker for anti-tumor therapy
CA3196737A1 (en) 2020-09-24 2022-03-31 Massimiliano Mazzone Combination of p2y6 inhibitors and immune checkpoint inhibitors
CA3195687A1 (en) 2020-09-25 2022-03-31 Ablynx Nv Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022133050A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Gpc3 binding molecules and uses thereof
WO2022133089A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea6 binding molecules and uses thereof
AU2021403089A1 (en) * 2020-12-18 2023-07-13 Bioardis, Llc Mesothelin binding molecules and uses thereof
KR20230125808A (ko) * 2020-12-18 2023-08-29 바이오아르디스 엘엘씨 EpCAM 결합 분자 및 이의 사용
US11897951B2 (en) 2020-12-18 2024-02-13 Ablynx N.V. Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
WO2022136693A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CA3205010A1 (en) * 2020-12-23 2022-06-30 Numab Therapeutics AG Antibody variable domains and antibodies having decreased immunogenicity
CA3206124A1 (en) 2020-12-24 2022-06-30 Vib Vzw Non-blocking human ccr8 binders
CA3206125A1 (en) 2020-12-24 2022-06-30 Vib Vzw Murine cross-reactive human ccr8 binders
US20240076391A1 (en) 2020-12-24 2024-03-07 Oncurious Nv Human ccr8 binders
IL304929A (en) 2021-02-05 2023-10-01 Vib Vzw [Be/Be Sarbevirus binders
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
US20240130999A1 (en) 2021-02-17 2024-04-25 Vib Vzw Inhibition of SLC4A4 in the Treatment of Cancer
IL305318A (en) 2021-02-19 2023-10-01 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2022199804A1 (en) 2021-03-24 2022-09-29 Vib Vzw Nek6 inhibition to treat als and ftd
WO2022216157A1 (en) 2021-04-09 2022-10-13 Stichting Radboud Universiteit Off the shelf proximity biotinylation enzyme
WO2022242892A1 (en) 2021-05-17 2022-11-24 Université de Liège Anti-cd38 single-domain antibodies in disease monitoring and treatment
WO2022258606A1 (en) 2021-06-07 2022-12-15 Gadeta B.V. Delta T-cell or Gamma T-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
JP2024523921A (ja) 2021-06-23 2024-07-02 フエー・イー・ベー・フエー・ゼツト・ウエー 特異的バインダーの選択手段及び方法
CN117580865A (zh) 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
US20250336476A1 (en) * 2021-07-12 2025-10-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and sytems for nanobody humanization
EP4378954A4 (en) 2021-07-30 2025-05-21 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-pvrig/anti-tigit bispecific antibody and application
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
US20240271186A1 (en) 2021-08-03 2024-08-15 Wageningen Universiteit Argonaute-based nucleic acid detection system
EP4428156A4 (en) 2021-12-03 2025-05-28 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF
IL313552A (en) 2021-12-17 2024-08-01 Ablynx Nv Polypeptides containing single immunoglobulin variable sites targeting tcraβ, cd33, and cd123
JP2025501206A (ja) 2021-12-31 2025-01-17 山▲東▼先声生物制▲薬▼有限公司 Ｇｐｒｃ５ｄ抗体及びその応用
US20250304664A1 (en) 2022-01-12 2025-10-02 Vib Vzw Human NTCP Binders For Therapeutic Use And Liver-Specific Targeted Delivery
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
EP4508082A1 (en) 2022-04-13 2025-02-19 Vib Vzw An ltbr agonist in combination therapy against cancer
CA3249283A1 (en) 2022-05-18 2023-11-23 Vib Vzw BINDERS OF SARBECOVIRUS SPICULE S2 SUBUNITS
WO2023227594A1 (en) 2022-05-24 2023-11-30 Gadeta Bv Novel deltat-cell receptor chains, gammat-cell receptor chains, or parts thereof
KR20250021313A (ko) 2022-06-06 2025-02-12 산둥심시어 바이오파마슈티칼 씨오., 엘티디. Bcma, gprc5d 및 t 세포를 표적으로 하는 다중특이적 항체 및 그 응용
WO2023237541A1 (en) 2022-06-07 2023-12-14 Gadeta B.V. Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response
WO2024003873A1 (en) 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Single variable domain antibodies against tumor necrosis factor-alpha
US20250304677A1 (en) 2022-07-04 2025-10-02 Vib Vzw Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
KR102749341B1 (ko) 2022-07-08 2025-01-06 노보 노르디스크 에이/에스 FVIII(a)를 치환할 수 있는 매우 강력한 ISVD 화합물
US20240075068A1 (en) 2022-07-15 2024-03-07 Gadeta B.V. Novel soluble gamma T-cell (or soluble delta T-cell) receptor chains (or soluble gammadelta T-cell receptors) or fragments thereof that mediate an anti-tumour or an anti-infective response
AU2023313033A1 (en) 2022-07-27 2025-03-13 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
EP4615493A1 (en) 2022-11-08 2025-09-17 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4620974A1 (en) 2022-11-15 2025-09-24 Oricell Therapeutics Co., Ltd. Anti-afp/hla02 tcr-like antibody and use thereof
CN120379763A (zh) 2022-11-15 2025-07-25 Imec 非营利协会 用于液滴操控的方法和系统
WO2024126685A1 (en) * 2022-12-15 2024-06-20 Institut National de la Santé et de la Recherche Médicale Single-domain antibody targeting von wilebrand factor a3-domain
WO2024126805A1 (en) 2022-12-15 2024-06-20 Aarhus Universitet Synthetic activation of multimeric transmembrane receptors
US20260042836A1 (en) 2022-12-19 2026-02-12 Umc Utrecht Holding B.V. Btn2a1 binding peptide
AR131494A1 (es) 2022-12-23 2025-03-26 Ablynx Nv Vehículos de conjugación a base de proteína
EP4655324A1 (en) 2023-01-27 2025-12-03 Vib Vzw Cd163-binding conjugates
WO2024156881A1 (en) 2023-01-27 2024-08-02 Vib Vzw CD8b-BINDING POLYPEPTIDES
WO2024165710A1 (en) 2023-02-09 2024-08-15 Seni-Preps B.V. Immunoglobulin single variable domains that inhibit urease and use thereof
AU2024221136A1 (en) 2023-02-17 2025-10-02 Ablynx N.V. Polypeptides binding to the neonatal fc receptor
WO2024175787A1 (en) 2023-02-24 2024-08-29 Vrije Universiteit Brussel Anti-inflammatory pannexin 1 channel inhibitors
CN121194987A (zh) 2023-03-14 2025-12-23 奥尔胡斯大学 基因改变的nfr5受体激酶
CN121358771A (zh) 2023-04-03 2026-01-16 非营利性组织佛兰芒综合大学生物技术研究所 血-脑屏障穿越抗体
CN121511260A (zh) 2023-05-11 2026-02-10 非营利性组织佛兰芒综合大学生物技术研究所 SLC4A4/NBCe1抑制剂
AU2024276787A1 (en) 2023-05-23 2026-01-15 Allygen Group Pd-l1 and trop-2 targeting conjugates comprising effector molecules and uses thereof
WO2024251826A1 (en) 2023-06-05 2024-12-12 Vib Vzw Glyco-engineered antibody-drug-conjugates comprising an oxime linker
WO2024251981A1 (en) 2023-06-09 2024-12-12 Umc Utrecht Holding B.V. Detecting and/or modulating susceptibility to btn2a1 and/or btn3a1 targeting therapeutics
WO2024261344A1 (en) 2023-06-23 2024-12-26 Vib Vzw Novel binders targeting the multi-drug resistant pathogen acinetobacter baumannii
EP4483951A1 (en) 2023-06-30 2025-01-01 Université de Liège Single-domain antibody for inhibition of neutrophil elastase activity
GB202314424D0 (en) 2023-09-20 2023-11-01 Cambridge Entpr Ltd A conjugate
TW202532432A (zh) 2023-09-22 2025-08-16 比利時商艾伯霖克斯公司 二及多價白蛋白結合劑
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025109176A1 (en) 2023-11-22 2025-05-30 Exevir Bio Bv Optimized sarbecovirus spike s2 subunit binders and compositions comprising the same
WO2025125577A1 (en) 2023-12-14 2025-06-19 Vib Vzw Antibodies against influenza b virus
WO2025133166A1 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based carriers for site-specific amine conjugation
WO2025133253A2 (en) 2023-12-22 2025-06-26 Ablynx Nv Protein-based conjugation carriers for intranuclear delivery
WO2025154058A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect hsp70 nanobodies and uses thereof
WO2025154056A1 (en) 2024-01-21 2025-07-24 Ibi-Ag Innovative Bio Insecticides Ltd. Anti-insect cda nanobodies and uses thereof
WO2025167664A1 (zh) * 2024-02-07 2025-08-14 原启生物科技(上海)有限责任公司 Ror1抗原结合蛋白及其用途
WO2025181155A1 (en) 2024-02-26 2025-09-04 Vib Vzw Human beta-glucocerebrosidase binders and uses thereof
WO2025196308A1 (en) 2024-03-22 2025-09-25 Vib Vzw Means and methods for displaying fc-containing proteins on cells and selection thereof
WO2025219231A1 (en) 2024-04-15 2025-10-23 Vib Vzw Computer-implemented means and methods for the de novo design of antibodies targeting a specific epitope
US20260007757A1 (en) 2024-06-18 2026-01-08 Ablynx Nv Antibody-recruiting molecules
WO2026008665A1 (en) 2024-07-01 2026-01-08 Vib Vzw Binders of the pd-1•pd-l1 complex and their use
WO2026027659A1 (en) 2024-07-31 2026-02-05 Seni-Preps B.V. Improved immunoglobulin single variable domains that inhibit urease and use thereof

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5238919A (en) * 1986-05-30 1993-08-24 Scipps Clinic And Research Foundation Peptides that inhibit von Willebrand Factor binding to the platelet SPIB receptor
DE3853740T2 (de) 1987-06-10 1995-11-09 Dana Farber Cancer Inst Inc Bifunktionelle Antikörperkonstruktionen und Verfahren zur selektiven Tötung von Zellbeständen.
US5200510A (en) 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE158180T1 (de) 1991-06-21 1997-10-15 Univ Cincinnati Oral verabreichbare therapeutische proteine und herstellungsverfahren
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ES2165851T3 (es) 1991-11-25 2002-04-01 Enzon Inc Proteinas multivalentes que se unen a antigenos.
PT651805E (pt) 1992-07-17 2007-02-28 Dana Farber Cancer Inst Inc Método de ligação intracelular de moléculas-alvo
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
EP0628078B1 (en) 1992-12-11 1999-12-08 The Dow Chemical Company Multivalent single chain antibodies
ATE167396T1 (de) 1993-02-22 1998-07-15 Alza Corp Mittel zur oralen gabe von wirkstoffen
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
GB9311454D0 (en) 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
ATE301201T1 (de) 1993-06-07 2005-08-15 Vical Inc Für die gentherapie verwendbare plasmide
CA2162878A1 (en) 1993-06-09 1994-12-22 Leon Gerardus Joseph Frenken Process for producing fusion proteins comprising scfv fragments by a transformed mould
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6091639A (en) 1993-08-27 2000-07-18 Kabushiki Kaisha Toshiba Non-volatile semiconductor memory device and data programming method
US6146826A (en) 1993-09-10 2000-11-14 The Trustees Of Columbia University In The City Of New York Green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
CA2183667A1 (en) 1994-02-22 1995-08-24 Wayne A. Marasco Nucleic acid delivery system, method of synthesis and uses thereof
US5670132A (en) * 1994-09-20 1997-09-23 Immunomedics, Inc. Modified radioantibody fragments for reduced renal uptake
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
EP0795608B1 (en) * 1994-11-30 2003-04-09 Ajinomoto Co., Inc. Antithrombotic agent and anti-von willebrand factor monoclonal antibodies
AU4964896A (en) 1995-01-19 1996-08-07 Research Foundation Of The State University Of New York, The Genes encoding an insect calcium channel
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5693492A (en) 1995-05-05 1997-12-02 Merck & Co., Inc. DNA encoding glutamate gated chloride channels
AU723325B2 (en) 1995-06-23 2000-08-24 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
EP0851874B1 (en) 1995-09-22 1999-09-15 Novo Nordisk A/S Novel variants of green fluorescent protein, gfp
JP2000508892A (ja) 1996-04-04 2000-07-18 ユニリーバー・ナームローゼ・ベンノートシャープ 多価および多特異的抗原結合タンパク
US6027881A (en) 1996-05-08 2000-02-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6124128A (en) 1996-08-16 2000-09-26 The Regents Of The University Of California Long wavelength engineered fluorescent proteins
WO1998021355A1 (en) 1996-11-15 1998-05-22 Life Technologies, Inc. Mutants of green fluorescent protein
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
CA2297692A1 (en) 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
US5895466A (en) 1997-08-19 1999-04-20 At&T Corp Automated natural language understanding customer service system
ATE461282T1 (de) * 1997-10-27 2010-04-15 Bac Ip Bv Multivalente antigenbindende proteine
BR9907241A (pt) 1998-01-26 2000-10-17 Unilever Nv Biblioteca de expressão, processo para preparar a mesma, uso de uma fonte não imunizada de sequências de ácido nucleico, e, processos para preparar fragmentos de anticorpos e, para preparar um anticorpo
WO1999042077A2 (en) 1998-02-19 1999-08-26 Xcyte Therapies, Inc. Compositions and methods for regulating lymphocyte activation
ATE535154T1 (de) * 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
CZ121599A3 (cs) 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
EP0967284A1 (en) 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
CA2336929C (en) 1998-07-06 2005-10-04 Euroscreen S.A. High-throughput screening diagnostic and/or dosage method of an agonist and/or an antagonist for a calcium-coupled receptor
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
EP1124856A1 (en) * 1998-10-23 2001-08-22 The Brigham And Women's Hospital, Inc. Conformation-specific anti-von willebrand factor antibodies
EP1002861A1 (en) 1998-10-26 2000-05-24 Unilever Plc Antigen-binding proteins comprising a linker which confers restricted conformational flexibility
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
BR9916765A (pt) 1999-01-05 2001-09-25 Unilever Nv Processo para produzir um material imunoadsorvente, uso de uma proteìna que é ligada por meio de uma ligação covalente a um fragmento de anticorpo, material imunadsorvente, uso de um material, e, kit de teste diagnóstico
EP1144616B2 (en) 1999-01-19 2009-01-14 Unilever Plc Method for producing antibody fragments
JP2002535993A (ja) 1999-02-05 2002-10-29 リイクスニフェルシタイト ライデン 組換え体細胞における代謝物の生合成を変調する方法
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
AU784108B2 (en) 1999-03-15 2006-02-02 University Of British Columbia, The Methods and reagents for modulating cholesterol levels
CN1252264C (zh) 1999-04-22 2006-04-19 荷兰联合利华有限公司 利用单价抗原－结合蛋白抑制病毒感染
NZ529785A (en) 1999-06-18 2005-09-30 Cv Therapeutics Inc Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter protein ABC1
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
AU6322900A (en) 1999-08-02 2001-02-19 Keygene N.V. Method for generating resistance against cgmmv in plants, genetic constructs for use in said method, and cgmmv-resistant plants obtained via said method
GB9922124D0 (en) 1999-09-17 1999-11-17 Pfizer Ltd Phosphodiesterase enzymes
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
DE19955408A1 (de) 1999-11-18 2001-05-23 Bayer Ag GABA-B-Rezeptoren
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
ATE428733T1 (de) 2000-03-14 2009-05-15 Unilever Nv Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
EP1328626B1 (en) 2000-05-26 2013-04-17 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6741957B1 (en) 2000-07-21 2004-05-25 Daimlerchrysler Corporation Analytical tire model for vehicle durability and ride comfort analysis
AU2002211658A1 (en) * 2000-10-13 2002-04-22 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
ATE513854T1 (de) 2000-12-13 2011-07-15 Bac Ip B V Proteinraster aus variablen domänen der schweren immunoglobulinkette von kamelen
GB0031448D0 (en) 2000-12-22 2001-02-07 Leuven K U Res & Dev Inhibition of the vWF-collagen interaction by anti-human vWF monoclonal antibody (82D6A3) results in abolition of in vivo arterial platelet thrombus formation
US7054297B1 (en) 2000-12-28 2006-05-30 Cisco Technology, Inc. Distribution of packets to high data rate communications devices using multicast protocols
DE10105526B4 (de) 2001-02-07 2004-12-23 Robert Bosch Gmbh Verfahren zur Herstellung einer Klappenanordnung
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
KR100599789B1 (ko) 2001-12-03 2006-07-12 삼성에스디아이 주식회사 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20050136056A1 (en) * 2002-07-29 2005-06-23 Shunsuke Kageyama Pharmaceutical composition for the treatment of thrombocytopenia
ATE512364T1 (de) * 2002-08-07 2011-06-15 Ablynx Nv Modulation der blutplättchen-adhäsion basierend auf dem oberflächen-exponierten beta-switch loop des blutplättchen-glycoproteins ib-alpha
US7004940B2 (en) 2002-10-10 2006-02-28 Ethicon, Inc. Devices for performing thermal ablation having movable ultrasound transducers
WO2004037999A2 (en) 2002-10-23 2004-05-06 Ludwig Institute For Cancer Research A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
AU2003286002B2 (en) 2002-11-08 2011-06-16 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
KR20050092029A (ko) 2003-01-10 2005-09-16 아블린쓰 엔.브이. 폰 빌레브란트 인자(ｖＷＦ) 또는 콜라겐에 대한낙타과로부터의 재조합 ＶＨＨ 단일 도메인 항체
EP2221317A3 (en) * 2003-06-30 2011-07-27 Domantis Limited PEGylated single domain antibodies (dAb)
AU2003283136A1 (en) 2003-11-07 2005-05-26 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
US7180370B2 (en) 2004-09-01 2007-02-20 Micron Technology, Inc. CMOS amplifiers with frequency compensating capacitors
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2583017A1 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
AU2006205900B8 (en) 2005-01-14 2012-04-05 Ablynx N.V. Methods and assays for distinguishing between different forms of diseases and disorders characterized by thrombocytopenia and/or by spontaneous interaction between Von Willebrand Factor (vWF) and platelets
LT2444424T (lt) 2005-05-20 2018-10-25 Ablynx N.V. Pagerintos tm nanodalelės, skirtos agregacijos sąlygotų sutrikimų gydymui
WO2008049881A2 (en) 2006-10-25 2008-05-02 Umc Utrecht Holding Bv Polypeptides and pharmaceutical compositions comprising the same for the prevention and treatment of complications associated with infectious diseases
US20110158996A1 (en) * 2008-03-21 2011-06-30 Ablynx N.V. Von willebrand factor specific binders and methods of use therefor

Also Published As

Publication number Publication date
CN101213214A (zh) 2008-07-02
HUE039846T2 (hu) 2019-02-28
BRPI0609797A2 (pt) 2010-04-27
NO2021020I1 (no) 2021-05-20
WO2006122825A9 (en) 2007-03-29
WO2006122825A3 (en) 2007-10-04
CY2019006I1 (el) 2020-05-29
ES2852423T3 (es) 2021-09-13
US20100330084A1 (en) 2010-12-30
EP2444424A1 (en) 2012-04-25
AU2006249090B2 (en) 2012-08-23
LUC00099I2 (member.php) 2019-12-27
NO345342B1 (no) 2020-12-21
CA2608873A1 (en) 2006-11-23
PL2444424T3 (pl) 2019-01-31
PT2444424T (pt) 2018-11-09
AU2006249090A1 (en) 2006-11-23
RU2007147381A (ru) 2009-06-27
CN101213214B (zh) 2014-06-25
LT2444424T (lt) 2018-10-25
IL187168A (en) 2015-05-31
ZA200709570B (en) 2008-10-29
LTC2444424I2 (lt) 2020-07-27
EP2007814A2 (en) 2008-12-31
MX2007014564A (es) 2008-02-07
NL300966I1 (nl) 2019-02-13
DK2444424T3 (en) 2018-12-03
CY2019006I2 (el) 2020-05-29
AU2006249090A8 (en) 2006-11-23
US8372398B2 (en) 2013-02-12
EP2444424B1 (en) 2018-08-08
NO20190279A1 (no) 2007-12-17
CY1122579T1 (el) 2020-05-29
EP3243839A1 (en) 2017-11-15
PL3415535T3 (pl) 2021-06-14
WO2006122825A2 (en) 2006-11-23
CA2608873C (en) 2017-04-25
US20100022452A1 (en) 2010-01-28
JP2008539775A (ja) 2008-11-20
NZ563392A (en) 2009-12-24
FR19C1005I2 (fr) 2020-01-31
LUC00099I1 (member.php) 2019-02-12
RU2433139C2 (ru) 2011-11-10
LTPA2019504I1 (lt) 2020-07-27
BE2019C503I2 (member.php) 2025-12-10
HUS1900005I1 (hu) 2019-03-28
FR19C1005I1 (fr) 2019-03-22
ES2694247T3 (es) 2018-12-19
TR201815552T4 (tr) 2018-11-21
EP3415535B1 (en) 2020-12-09
SI2444424T1 (sl) 2018-10-30
NL300966I2 (nl) 2019-04-11
BRPI0609797B1 (pt) 2018-07-03
CA2960105A1 (en) 2006-11-23
KR20080023301A (ko) 2008-03-13
EP3415535A1 (en) 2018-12-19
PT3415535T (pt) 2021-02-02
US7807162B2 (en) 2010-10-05
IL208607A0 (en) 2010-12-30
JP4986997B2 (ja) 2012-07-25
KR101414438B1 (ko) 2014-07-10
IL187168A0 (en) 2008-02-09
US20130136736A1 (en) 2013-05-30
BRPI0609797B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO20076475L (no) Enkeltdomene VHH antilegemer mot Van Willebrand faktor
NO20073808L (no) BCMA polypeptider og anvendelser derav
WO2008074867A3 (en) Anti-fc-receptor single domain antibodies (nanobodies-tm) and therapeutic use
PT2499165T (pt) Preparações que contêm o fator de von willebrand (vwf), e métodos, kits e utilizações relacionadas com as mesmas
IL250946B (en) Nanobodies against tumor necrosis factor-alpha (tnf-alpha)
WO2007102149A3 (en) Hydrazido derivatives of hyaluronic acid
PE20090726A1 (es) Anticuerpos anti-ige apoptoticos
MX350962B (es) Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion.
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
NO20082240L (no) GLP-2 imitatorstoff, polypeptider, sammensetninger, fremgangsmater og anvendelser
ATE541283T1 (de) Verfahren zum mischen von farben in einem display
WO2010066411A3 (en) Polypeptides having cellobiohydrolase ii activity
ATE477321T1 (de) Aviäre telomerase reverse transkriptase
CY1116000T1 (el) Υποκατεστημενες πυραζολες, συνθεσεις που τις περιεχουν, μεθοδος παραγωγης και χρηση
NO20083497L (no) Modulering av bendannelse
EP4272822A3 (en) Adamts binding immunoglobulins
WO2009050277A3 (en) Edta resistant s100a12 complexes (erac)
RU2013112918A (ru) Способы и материалы для придания зубам внешней белизны
WO2005024006A3 (en) Coagulation factor vii polypeptides
WO2008005470A3 (en) Polypeptides that bind membrane proteins
WO2007045019A3 (en) Polyoleosins
MY146033A (en) Adhesive system and method
WO2008002548A3 (en) Novel human acidic mammalian chitinase and use thereof
ATE512159T1 (de) Cyclodipeptidsynthetasen und ihre verwendung zur synthese von cyclo(leu-leu)cyclodipeptid
WO2009120378A3 (en) Methods for increasing absorption of peptides, peptidomimetics, and other gastrointestinal transport protein substrates

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application